RxDoctor Payments Data

Gopika Gangupantula, MD

Family Medicine · Modesto, CANPI 1245318138

Payments from drug & device makers

$107,064in general payments, 2019–2025

Across 592 payments — averaging $180.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$84K
  • Xeris Pharmaceuticals, Inc.$14K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Corcept Therapeutics$652
  • Boehringer Ingelheim$559
  • plus $4K from 22 others

What the payments were for

  • Consulting fees$5,1755%
  • Speaking & faculty fees$65,70061%
  • Travel & lodging$22,90521%
  • Food & beverage$13,20312%
  • Education$810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$107,064 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$166,727
Medicare patients
175
Services billed
2,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide274$384,560
JardianceEmpagliflozin138$183,802
TrulicityDulaglutide100$172,957
Tresiba Flextouch U-100Insulin Degludec104$103,992
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog156$83,395
Humalog Kwikpen U-100Insulin Lispro213$83,030
MounjaroTirzepatide40$74,115
Fiasp FlextouchInsulin Aspart (Niacinamide)51$63,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog188$35,148
Novolog FlexpenInsulin Aspart99$35,045
JanuviaSitagliptin Phosphate20$34,516
Nano 2nd Gen Pen NeedlePen Needle, Diabetic241$33,484
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$33,477
RybelsusSemaglutide12$23,516
Tresiba Flextouch U-200Insulin Degludec13$20,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,839$408,076286 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$84,375$248,514153 claims
Boehringer IngelheimJardiance, Tradjenta$559$200,218156 claims
MerckJanuvia, Janumet Xr$115$41,58532 claims
BayerKerendia$341$8,08411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →